3Delevaux I, Andre M, Colombier M, et al. Can procalcitonin measurement help in differentiating between bacterial infection and other kinds of inflammatory processes. Ann Rheum Dis ,2003,62 (4) :337 - 340.
4Jereb M, Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. Wien Klin Wochenschr,2006,118 (5-6) :170 - 174.
5Hirakata Y, Yanagihara K, Kurihara S, et al. Comparison of usefulness of plasma procaleitonin and C-reactive protein measurements for estiroation of severity in adults with community-acquired pneumonia. Diagn Microbiol Infect Dis, 2008,61 ( 2 ) : 170 - 174.
6Christ-Crain M,Stolz D, Bingisser R,et al. Procalcitonin guidance of antibiotic therapy in Communtity-acquired pneumonia:a tandomized trial. Am J Respir Crit Care Med ,2006,174 (1) :84 -93.
7Menendez R, Cavaleanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax,2008, 63(5) :447 -452.
8Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD : a randomized , controlled trial comparing procalcitonin-guidance with standard therapy. Chest,2007,131 ( 1 ) : 9-19.
9Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community - acquired pneumonia. Intensive Care Med,2006,32(3) :469 -472.
10Oppert M, Reinicke A, Muller C, et al. Elevations in procaleitonin but not C-reactive protein are associated with pneumonia after cardiopulmonary resuscitation. Resuscitation ,2002,53 (2) : 167 - 170.
